{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T17:24:44Z","timestamp":1783790684773,"version":"3.55.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T00:00:00Z","timestamp":1546560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["15ck0106059h0002"],"award-info":[{"award-number":["15ck0106059h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pharmacotherapy is generally recommended to treat patients with delirium. We sought to describe the current practice, effectiveness, and adverse effects of pharmacotherapy for hypoactive delirium in patients with advanced cancer, and to explore predictors of the deterioration of delirium symptoms after starting pharmacotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Subjects, Materials, and Methods<\/jats:title>\n                  <jats:p>We included data of patients with advanced cancer who were diagnosed with hypoactive delirium and received pharmacotherapy for treatment of delirium. This was a pharmacovigilance study characterized by prospective registries and systematic data-recording using internet technology, conducted among 38 palliative care teams and\/or units. The severity of delirium and other outcomes were assessed using established measures at days 0 (T0), 3 (T1), and 7 (T2).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Available data were obtained from 218 patients. The most frequently used agent was haloperidol (37%). A total of 67 and 42 patients (31% and 19%) had died or discontinued pharmacotherapy by T1 and T2, respectively. Delirium symptoms deteriorated between T0 and T1, but this trend did not reach statistical significance. The most prevalent adverse event was sedation (9%). Delirium severity worsened after starting pharmacotherapy in 121 patients (56%) at T1. In patients whose death was expected within a few days and those with delirium caused by organ failure, symptoms of delirium were significantly more likely to deteriorate after starting pharmacotherapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Current pharmacotherapy for hypoactive delirium in patients with advanced cancer is not recommended, especially in those whose death is expected within a few days and in those with delirium caused by organ failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2018-0242","type":"journal-article","created":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T18:34:19Z","timestamp":1546626859000},"page":"e574-e582","source":"Crossref","is-referenced-by-count":18,"title":["Current Pharmacotherapy Does Not Improve Severity of Hypoactive Delirium in Patients with Advanced Cancer: Pharmacological Audit Study of Safety and Efficacy in Real World (Phase-R)"],"prefix":"10.1093","volume":"24","author":[{"given":"Toru","family":"Okuyama","sequence":"first","affiliation":[{"name":"Division of Psycho-Oncology and Palliative Care, Nagoya City University Hospital, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan"},{"name":"Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yoshiuchi","sequence":"additional","affiliation":[{"name":"Department of Stress Sciences and Psychosomatic Medicine, Graduate School of Medicine, The University of Tokyo, Hongo, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asao","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Psycho-Oncology Service, National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Iwase","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Saitama Medical University, Morohongo Moroyama-machi, Iruma-gun, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naosuke","family":"Yokomichi","sequence":"additional","affiliation":[{"name":"Seirei Hospice, Seirei Mikatahara General Hospital, Mikatahara-cho, kita-ku, Hamamatsu, Shizuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Sakashita","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Kobe University Graduate School of Medicine, Kusunoki-cho, chuoh-ku, Kobe, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Tagami","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Tohoku University School of Medicine, Seiryo-machi, Aoba-ku, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Hokkaido Medical Center, Yamanote, Nishi-ku, Sapporo, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Psycho-Oncology, National Cancer Center Hospital, Tsukiji, Chuou-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Akechi","sequence":"additional","affiliation":[{"name":"Division of Psycho-Oncology and Palliative Care, Nagoya City University Hospital, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan"},{"name":"Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of Phase-R Delirium Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,4]]},"reference":[{"key":"2021122507241319900_R1","volume-title":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders","year":"2013","edition":"5th ed"},{"key":"2021122507241319900_R2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra052321","article-title":"Delirium in older persons","volume":"354","author":"Inouye","year":"2006","journal-title":"N Engl J Med"},{"key":"2021122507241319900_R3","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1191\/0269216304pm879oa","article-title":"Delirium in advanced cancer patients","volume":"18","author":"Centeno","year":"2004","journal-title":"Palliat Med"},{"key":"2021122507241319900_R4","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/ageing\/afl005","article-title":"Occurrence and outcome of delirium in medical in-patients: A systematic literature review","volume":"35","author":"Siddiqi","year":"2006","journal-title":"Age Ageing"},{"key":"2021122507241319900_R5","first-page":"1","article-title":"Practice guideline for the treatment of patients with delirium","volume":"156","author":"American Psychiatric Association","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2021122507241319900_R6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1017\/S1478951504040234","article-title":"The delirium subtypes: A review of prevalence, phenomenology, pathophysiology, and treatment response","volume":"2","author":"Stagno","year":"2004","journal-title":"Palliat Support Care"},{"key":"2021122507241319900_R7","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/0269216312457214","article-title":"Delirium prevalence, incidence, and implications for screening in specialist palliative care inpatient settings: A systematic review","volume":"27","author":"Hosie","year":"2013","journal-title":"Palliat Med"},{"key":"2021122507241319900_R8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1176\/appi.psy.43.3.183","article-title":"The delirium experience: Delirium recall and delirium-related distress in hospitalized patients with cancer, their spouses\/caregivers, and their nurses","volume":"43","author":"Breitbart","year":"2002","journal-title":"Psychosomatics"},{"key":"2021122507241319900_R9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jpainsymman.2007.01.012","article-title":"Terminal delirium: Recommendations from bereaved families' experiences","volume":"34","author":"Morita","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"2021122507241319900_R10","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1200\/JCO.2011.39.8784","article-title":"Evidence-based treatment of delirium in patients with cancer","volume":"30","author":"Breitbart","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122507241319900_R11","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11920-015-0550-8","article-title":"Management of delirium in palliative care: A review","volume":"17","author":"Grassi","year":"2015","journal-title":"Curr Psychiatry Rep"},{"key":"2021122507241319900_R12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1017\/S1478951511000368","article-title":"An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients","volume":"9","author":"Boettger","year":"2011","journal-title":"Palliat Support Care"},{"key":"2021122507241319900_R13","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1176\/jnp.6.1.66","article-title":"Efficacy of neuroleptics for hypoactive delirium","volume":"6","author":"Platt","year":"1994","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2021122507241319900_R14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: A randomized clinical trial","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2021122507241319900_R15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1176\/appi.psy.43.3.175","article-title":"An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients","volume":"43","author":"Breitbart","year":"2002","journal-title":"Psychosomatics"},{"key":"2021122507241319900_R16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/CCM.0b013e3181b9e302","article-title":"Efficacy and safety of quetiapine in critically ill patients with delirium: A prospective, multicenter, randomized, double-blind, placebo-controlled pilot study","volume":"38","author":"Devlin","year":"2010","journal-title":"Crit Care Med"},{"key":"2021122507241319900_R17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3109\/00048674.2011.543411","article-title":"Aripiprazole and haloperidol in the treatment of delirium","volume":"45","author":"Boettger","year":"2011","journal-title":"Aust N Z J Psychiatry"},{"key":"2021122507241319900_R18","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/jgs.13281","article-title":"American Geriatrics Society abstracted clinical practice guideline for postoperative delirium in older adults","volume":"63","author":"American Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults","year":"2015","journal-title":"J Am Geriatr Soc"},{"key":"2021122507241319900_R19","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1089\/jpm.2012.0111","article-title":"Pharmacovigilance in hospice\/palliative care: Rapid report of net clinical effect of metoclopramide","volume":"15","author":"Currow","year":"2012","journal-title":"J Palliat Med"},{"key":"2021122507241319900_R20","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ajp.2017.11.028","article-title":"First- and second-line pharmacological treatment for delirium in general hospital setting-Retrospective analysis","volume":"32","author":"Wada","year":"2018","journal-title":"Asian J Psychiatr"},{"key":"2021122507241319900_R21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00004714-199906000-00018","article-title":"Trazodone in the treatment of delirium","volume":"19","author":"Okamoto","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"2021122507241319900_R22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/jjco\/hyv100","article-title":"Prevalence, course and factors associated with delirium in elderly patients with advanced cancer: A longitudinal observational study","volume":"45","author":"Uchida","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"2021122507241319900_R23","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/jnp.2008.20.2.185","article-title":"A new data-based motor subtype schema for delirium","volume":"20","author":"Meagher","year":"2008","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2021122507241319900_R24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1176\/jnp.13.2.229","article-title":"Validation of the Delirium Rating Scale-revised-98: Comparison with the delirium rating scale and the cognitive test for delirium","volume":"13","author":"Trzepacz","year":"2001","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2021122507241319900_R25","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jpainsymman.2004.07.009","article-title":"Fast, systematic, and continuous delirium assessment in hospitalized patients: The nursing delirium screening scale","volume":"29","author":"Gaudreau","year":"2005","journal-title":"J Pain Symptom Manage"},{"key":"2021122507241319900_R26","first-page":"39","article-title":"Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale: Comparison with Western scales in the clinical double-blind studies of schizophrenic patients treated with either olanzapine or haloperidol","volume":"18","author":"Inada","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"key":"2021122507241319900_R27","first-page":"425","article-title":"Japanese version of the Delirium Rating Scale, Revised-98 (DRS-R98-J): Reliability and validity","volume":"51","author":"Kato","year":"2010","journal-title":"Psychosomatics"},{"key":"2021122507241319900_R28","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-684X-13-17","article-title":"The Richmond Agitation-Sedation Scale modified for palliative care inpatients (RASS-PAL): A pilot study exploring validity and feasibility in clinical practice","volume":"13","author":"Bush","year":"2014","journal-title":"BMC Palliat Care"},{"key":"2021122507241319900_R29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1191\/026921601678576185","article-title":"Communication Capacity Scale and Agitation Distress Scale to measure the severity of delirium in terminally ill cancer patients: A validation study","volume":"15","author":"Morita","year":"2001","journal-title":"Palliat Med"},{"key":"2021122507241319900_R30","author":"Japan Clinical Oncology Group"},{"key":"2021122507241319900_R31","author":"Japan Clinical Oncology Group"},{"key":"2021122507241319900_R32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/082585979601200102","article-title":"Palliative performance scale (PPS): A new tool","volume":"12","author":"Anderson","year":"1996","journal-title":"J Palliat Care"},{"key":"2021122507241319900_R33","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s005200050242","article-title":"The Palliative Prognostic Index: A scoring system for survival prediction of terminally ill cancer patients","volume":"7","author":"Morita","year":"1999","journal-title":"Support Care Cancer"},{"key":"2021122507241319900_R34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1001\/archinte.160.6.786","article-title":"Occurrence, causes, and outcome of delirium in patients with advanced cancer: A prospective study","volume":"160","author":"Lawlor","year":"2000","journal-title":"Arch Intern Med"},{"key":"2021122507241319900_R35","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0885-3924(01)00360-8","article-title":"Underlying pathologies and their associations with clinical features in terminal delirium of cancer patients","volume":"22","author":"Morita","year":"2001","journal-title":"J Pain Symptom Manage"},{"key":"2021122507241319900_R36","author":"Wolff"},{"key":"2021122507241319900_R37","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jama.2017.11468","article-title":"Effect of lorazepam with haloperidol vs haloperidol alone on agitated delirium in patients with advanced cancer receiving palliative care: A randomized clinical trial","volume":"318","author":"Hui","year":"2017","journal-title":"JAMA"},{"key":"2021122507241319900_R38","first-page":"345","volume-title":"Users' Guides to the Medical Literature: A Manual for Evidence-Based Practice","author":"Furukawa","year":"2014","edition":"3rd ed"},{"issue":"suppl 4","key":"2021122507241319900_R39","doi-asserted-by":"crossref","first-page":"iv143","DOI":"10.1093\/annonc\/mdy147","article-title":"Delirium in adult cancer patients: ESMO Clinical Practice Guidelines","volume":"29","author":"Bush","year":"2018","journal-title":"Ann Oncol"},{"key":"2021122507241319900_R40","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpainsymman.2014.05.009","article-title":"End-of-life delirium: Issues regarding recognition, optimal management and the role of sedation in the dying phase","volume":"48","author":"Bush","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122507241319900_R41","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1056\/NEJMra1411746","article-title":"Comfort care for patients dying in the hospital","volume":"373","author":"Blinderman","year":"2015","journal-title":"N Engl J Med"},{"key":"2021122507241319900_R42","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pon.4140","article-title":"The experiences of caregivers of patients with delirium, and their role in its management in palliative care settings: An integrative literature review","volume":"26","author":"Finucane","year":"2017","journal-title":"Psychooncology"},{"key":"2021122507241319900_R43","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1049909113486171","article-title":"Effect of leaflet-based intervention on family members of terminally ill patients with cancer having delirium: Historical control study","volume":"31","author":"Otani","year":"2014","journal-title":"Am J Hosp Palliat Care"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0242","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0242","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/e574\/41917514\/oncolo_24_7_e574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/7\/e574\/41917514\/oncolo_24_7_e574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:26:17Z","timestamp":1640417177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/7\/e574\/6439446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,4]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,1,4]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0242","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7,1]]},"published":{"date-parts":[[2019,1,4]]}}}